Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm.
Echocardiography
JAK2V617F mutation
Pulmonary hypertension
Journal
Medical principles and practice : international journal of the Kuwait University, Health Science Centre
ISSN: 1423-0151
Titre abrégé: Med Princ Pract
Pays: Switzerland
ID NLM: 8901334
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
10
2019
accepted:
16
02
2020
pubmed:
19
2
2020
medline:
22
7
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Pulmonary hypertension (PH) can complicate the course of myeloproliferative neoplasms (MPNs). Echocardiography is a useful noninvasive screening test for PH in populations at risk. We aimed to investigate the echocardiographic evidence of PH and clinical characteristics of patients with MPNs. This study included 197 patients with MPNs (mean age, 59 ± 14 years; females, 53%; mean disease duration, 3.4 ± 2.8 years). Clinical and laboratory characteristics, including JAK2V617F mutation status, were obtained. All participants underwent a comprehensive transthoracic echocardiographic examination. The echocardiographic evidence of PH was defined as systolic pulmonary artery pressure (SPAP) ≥40 mm Hg. Overall, 11 patients (5.5%) with SPAP ≥40 mm Hg had echocardiographic evidence of PH. Patients with myelofibrosis had echocardiographic evidence of PH more often than patients with other MPNs (p < 0.001). Disease duration since the diagnosis of MPNs was 6.7 ± 4.6 years in the PH group and 3.1 ± 2.5 years in the non-PH group (p < 0.001). There was a weak positive correlation between SPAP values and time since diagnosis (r = 0.236, p =0.001). JAK2V617F mutation was not associated with PH. In multivariate logistic regression analysis, the presence of myelofibrosis (odds ratio [OR]: 22.177, 95% CI: 4.480-109.790, p < 0.001), long disease duration (OR: 1.217, 95% CI: 1.024-1.447, p = 0.026), and high uric acid levels (OR: 1.868, 95% CI: 1.049-3.328, p = 0.034) were found to be related with the echocardiographic evidence of PH. Survival was worse in the PH group (p = 0.0001). Our results suggest that patients with myelofibrosis are more likely to develop PH than other MPNs patients. Disease duration may predict the development of PH in MPN patients.
Sections du résumé
BACKGROUND
Pulmonary hypertension (PH) can complicate the course of myeloproliferative neoplasms (MPNs). Echocardiography is a useful noninvasive screening test for PH in populations at risk. We aimed to investigate the echocardiographic evidence of PH and clinical characteristics of patients with MPNs.
METHODS
This study included 197 patients with MPNs (mean age, 59 ± 14 years; females, 53%; mean disease duration, 3.4 ± 2.8 years). Clinical and laboratory characteristics, including JAK2V617F mutation status, were obtained. All participants underwent a comprehensive transthoracic echocardiographic examination. The echocardiographic evidence of PH was defined as systolic pulmonary artery pressure (SPAP) ≥40 mm Hg.
RESULTS
Overall, 11 patients (5.5%) with SPAP ≥40 mm Hg had echocardiographic evidence of PH. Patients with myelofibrosis had echocardiographic evidence of PH more often than patients with other MPNs (p < 0.001). Disease duration since the diagnosis of MPNs was 6.7 ± 4.6 years in the PH group and 3.1 ± 2.5 years in the non-PH group (p < 0.001). There was a weak positive correlation between SPAP values and time since diagnosis (r = 0.236, p =0.001). JAK2V617F mutation was not associated with PH. In multivariate logistic regression analysis, the presence of myelofibrosis (odds ratio [OR]: 22.177, 95% CI: 4.480-109.790, p < 0.001), long disease duration (OR: 1.217, 95% CI: 1.024-1.447, p = 0.026), and high uric acid levels (OR: 1.868, 95% CI: 1.049-3.328, p = 0.034) were found to be related with the echocardiographic evidence of PH. Survival was worse in the PH group (p = 0.0001).
CONCLUSION
Our results suggest that patients with myelofibrosis are more likely to develop PH than other MPNs patients. Disease duration may predict the development of PH in MPN patients.
Identifiants
pubmed: 32069470
pii: 000506596
doi: 10.1159/000506596
pmc: PMC7511681
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-491Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Chest. 2001 Sep;120(3):801-8
pubmed: 11555513
Ann Hematol. 2016 Oct;95(10):1611-6
pubmed: 27468853
Chest. 2009 Mar;135(3):760-768
pubmed: 18849403
Eur Respir J. 2009 Jan;33(1):213-6
pubmed: 19118232
Am J Hematol. 1999 Feb;60(2):130-5
pubmed: 9929105
J Natl Med Assoc. 2006 Nov;98(11):1779-82
pubmed: 17128687
Mod Rheumatol. 2019 Nov;29(6):1031-1041
pubmed: 30334638
Eur J Intern Med. 2019 Oct;68:71-75
pubmed: 31421946
Leuk Lymphoma. 2014 Jan;55(1):223-5
pubmed: 23614764
Respiration. 2008;76(3):295-302
pubmed: 18160817
Circulation. 2012 May 1;125(17):2128-37
pubmed: 22451584
Clin Chest Med. 2013 Dec;34(4):753-78
pubmed: 24267303
Thorax. 2005 Dec;60(12):1031-4
pubmed: 16085731
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41
pubmed: 24355639